Table 2.

Incidence of thrombotic events and CNS hemorrhage from anti-VEGF therapies in patients with malignant gliomas

Study	Agent(s)	Number of patients	Number with DVT/PE	Number with CNS or Systemic Bleed	Number with stroke
Vredenburgh, JCO 200724	Bev/CPT	35	4 (11%)	1 (0.03%)	0
Vredenburgh, Clin Cancer Res59	Bev/CPT	32	3 (9%)	0	1 (3%)
Friedman20	Bev & Bev/CPT	167	11 (7%)	5 (3%)	9 (5%)
Sathornsumetee73	Bev/Erlotinib	57	3 (5%)	1 (2%)	1 (2%)
Kreisl85	Bev & Bev/CPT	48	6 (8%)	0	0
Gilbert55	Bev/CPT, Bev/TMZ	117	14 (12%)	9 (8%) 8 grade 1 or 2	1 (1%)
Lai et al.17	Bev	70	13 (19%)	2 (3%)CNS, 2(3%) GI	6 (9%)
Batchelor58	Cediranib	31	1 (1%)	0	0
Wen57	XL184	153	15 (10%)	7 (5%)	0